- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00772070
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD
This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose of TetraMenD at least 18 months earlier.
Primary Objective:
To evaluate and compare the antibody responses to a reduced dose of Menomune® in participants who had previously received a tetravalent meningococcal diphtheria toxoid conjugate vaccine to those responses in participants who received the same reduced dose of Menomune® but had not previously received any meningococcal vaccine.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Arkansas
-
Jonesboro, Arkansas, Forente stater, 72401
-
Little Rock, Arkansas, Forente stater, 72211
-
-
Massachusetts
-
Woburn, Massachusetts, Forente stater, 01801
-
-
Missouri
-
Bridgeton, Missouri, Forente stater, 63044
-
-
New York
-
Rochester, New York, Forente stater, 14620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15241
-
Sellersville, Pennsylvania, Forente stater, 18960
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23501
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria :
- Stage I
- Participant is healthy, as determined by medical history and physical examination.
- Participant is at least 3 years of age but not yet 6 years of age at the enrolment.
- For the TetraMenD group: received one dose of TetraMenD as a participant in trial 603-02 no less than 18 months prior to enrolment
- For the Control group: no previous history of any meningococcal vaccination
- Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.
- Stage II
- Participant is healthy, as determined by medical history and physical examination.
- Participant is at least 3 years of age but not yet 6 years of age at the time of enrollment in Stage 1.
- Enrolled in the Control group only and received one dose of the reduced dose Menomune at Stage 1.
- Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form.
Exclusion Criteria :
- Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc.)
- Known or suspected impairment of immunologic function
- Acute medical illness with or without fever within the last 72 hours or an axillary temperature (≥ 99.5ºF [≥ 37.5ºC]) at the time of inclusion
- For Stage I, history of documented invasive meningococcal disease or previous meningococcal vaccination with exception of those participants recruited from Trial 603-02.
- For Stage II, history of documented invasive meningococcal disease or participant did not receive Reduced-dose Menomune® six months prior.
- Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
- Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn
- Received any vaccine in the 28-day period prior to study vaccination, or scheduled to receive any vaccination during the 28-day period after study vaccination in Stage 1 of the trial.
- Suspected or known hypersensitivity to any of the vaccine components
- Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
- Enrolled in another clinical trial
- Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Previously received TetraMenD
Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
|
0.05 mL, Subcutaneous
Andre navn:
|
Eksperimentell: Meningococcal vaccine-naїve
Participants have never received a Meningococcal vaccine in the past.
|
0.05 mL, Subcutaneous
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination.
Tidsramme: Day 0 and Days 8 and 28 post-vaccination
|
Day 0 and Days 8 and 28 post-vaccination
|
Andre resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Activity to Each Vaccine Meningococcal Serogroups.
Tidsramme: Baseline to Day 8 and Day 28 post-vaccination
|
Baseline to Day 8 and Day 28 post-vaccination
|
Percentage of Participants Reporting Solicited Local and Systemic Reactions Within Days 0 to 7 Post-vaccination.
Tidsramme: Day 0 to 7 post-vaccination
|
Day 0 to 7 post-vaccination
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Infeksjoner
- Bakterielle infeksjoner
- Bakterielle infeksjoner og mykoser
- Gram-positive bakterielle infeksjoner
- Actinomycetales infeksjoner
- Corynebacterium-infeksjoner
- Difteri
- Meningitt
- Fysiologiske effekter av legemidler
- Immunologiske faktorer
- Vaksiner
Andre studie-ID-numre
- MTA17
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningitt | MeningokokkinfeksjonerForente stater
-
SanofiFullførtMeningitt | Meningokokkinfeksjoner | Meningokokk MeningittForente stater
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningitt | Meningokokkinfeksjoner | Meningokokk Meningitt | Invasiv meningokokksykdomForente stater
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningitt | Meningokokkinfeksjoner | Meningokokk MeningittForente stater, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningitt | MeningokokkinfeksjonForente stater
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningokokkinfeksjoner | Meningokokk MeningittForente stater
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningitt | Meningokokkinfeksjoner | Meningokokk MeningittForente stater
-
EuBiologics Co.,LtdFullførtInfeksjon, meningokokkKorea, Republikken
-
EuBiologics Co.,LtdFullførtInfeksjon, meningokokkKorea, Republikken
-
Sanofi Pasteur, a Sanofi CompanyFullførtMeningitt | Meningokokkinfeksjoner | Meningokokk MeningittFinland